Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A. Jo Chien, Andres Forero-Torres, Erin Ellis, Heather Han, Amy Clark, Kathy Albain, Judy C. Boughey, Nora T. Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-ReasorCatherine Parker, Marie C. Lee, Tufia Haddad, Ronald N. Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard Schwab, W. Fraser Symmans, Laura Van 'T Veer, Douglas Yee, Angela Demichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman

Research output: Contribution to journal › Article › peer-review

400 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences